Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.

导出原文传递

翻译打印收藏纠错

作者： Rasha,Eletreby ^[1] ; Magdy,El-Serafy ^[1] ; Mahmoud,Anees ^[2] ; Gamal,Kasem ^[2] ; Marwa,Salama ^[2] ; Reham,Elkhouly ^[2] ; Mostafa,Hamdy ^[3] ; Hisham,Abdel Haleem ^[4] ; Ehab,Kamal ^[5] ; Wael,Abdel-Razek ^[6] ; Rabab,Salama ^[1] ; Mohamed,Elshenawy ^[7] ; Ayman,Shafeek ^[8] ; Mohamed,Hassany ^[9] ; Manal H,El-Sayed ^[10] ; Yehia,El-Shazly ^[11] ; Gamal,Esmat ^[1]

作者单位： Endemic Medicine and Hepato-Gastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. ^[1] Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt. ^[2] Faiyum Viral Hepatitis Treatment Center, Faiyum, Egypt. ^[3] Internal Medicine Department, Faculty of Medicine, Minia University, Minia, Egypt. ^[4] Medical Research Division, National Research Centre, Giza, Egypt. ^[5] Hepatology Department, National Liver Institute, Menoufia University, Menoufia, Egypt. ^[6] Viral Hepatitis Treatment Center, Damietta, Egypt. ^[7] Viral Hepatitis Treatment Center, Imbaba Fever Hospital, Cairo, Egypt. ^[8] Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt. ^[9] Department of Pediatrics and Clinical Research Center (MASRI-CRC), Ain Shams University, Cairo, Egypt. ^[10] Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ^[11] Endemic Medicine and Hepato-Gastroentrology Department, Badr University, Cairo, Egypt. ^[12]

关键词 efficacy renal impairment safety sofosbuvir